OptiNose US Inc

OptiNose US Inc. is a specialty pharmaceutical company headquartered in Yardley, Pennsylvania. The company employs 168 full-time employees and generates an annual revenue of $77.5 million. OptiNose focuses on developing and commercializing products for patients treated by ear, nose and throat (ENT) and allergy specialists. Their flagship product, XHANCE® (fluticasone propionate) nasal spray, utilizes their proprietary Exhalation Delivery System™ (EDS®) to deliver a topically-acting corticosteroid. XHANCE is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of nasal polyps in adults and has shown positive results in clinical trials for chronic sinusitis. OptiNose differentiates itself through its innovative Exhalation Delivery System™, which offers a unique approach to delivering medication. The company's commitment to its employees and fostering a positive work culture is also a key differentiator. For more information about OptiNose US Inc., please visit their website at optinose.com.